Characteristics of patients with liver tumors deemed ineligible for enrollment on Children's Oncology Group trial AHEP1531: An opportunity to expand inclusion criteria and improve outcome
- 16 October 2024
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (1) , e31389
Abstract
Background: Specific patients with hepatoblastoma (HB) and hepatocellular carcinoma (HCC) do not meet eligibility criteria for Children's Oncology Group (COG) trials, limiting an understanding of how comorbidities affect the outcome. We define such a population for future‐focused care improvements.Methods: A questionnaire was sent to COG institutional principal investigators to obtain anonymized data regarding patients with a liver tumor diagnosis not enrolled on AHEP1531 due to ineligibility by trial criteria or other reasons (excluding parent/patient preference).Results: Responses received for 55 patients (38 HB, 4 HCC, and 13 not reported) included 12 excluded from further analysis due to various factors, including lack of additional information. Five patients were eligible but not enrolled due to pandemic‐related staffing issues (n = 1) or the best interest of the patient (physician preference, n = 1; risk for poor tolerance of chemotherapy, n = 1; not specified, n = 2). The remaining 38 patients included 1 ineligible due to a prior malignancy, 9 due to performance status, and 4 due to timing requirements. Thirty‐five of 38 patients were ineligible due to organ function criteria (pulmonary/oxygen requirement, n = 25; renal, n = 10; liver, n = 4; cardiac, n = 3). Seven patients were ineligible due to two or more organ function criteria. Twenty‐five of 38 patients were reported to have a preexisting condition including 4 patients with trisomy 18.Conclusions: Patients with HB, and potentially HCC, who are ineligible for COG trials are primarily patients with an oxygen requirement and/or renal insufficiency, often associated with preexisting congenital conditions. Such patients would benefit from future studies to improve outcomes.Keywords
This publication has 17 references indexed in Scilit:
- Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Children's Oncology Group Trial, AHEP0731Journal of Pediatric Surgery, 2022
- Hepatoblastoma in molecularly defined, congenital diseasesAmerican Journal of Medical Genetics Part A, 2022
- Doxorubicin in combination with cisplatin, 5‐flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group studyCancer, 2021
- Surveillance guidelines for children with trisomy 18American Journal of Medical Genetics Part A, 2021
- Surgical and anesthetic management for hepatectomy in two pediatric patients with trisomy 18, pulmonary hypertension, and hepatoblastomaPediatric Blood & Cancer, 2019
- Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastomaPediatric Blood & Cancer, 2018
- Therapeutic experience with hepatoblastoma associated with trisomy 18Pediatric Blood & Cancer, 2018
- Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International CollaborationThe Lancet Oncology, 2017
- Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility studyThe Lancet Oncology, 2013
- Hepatoblastoma and prune belly syndrome: a potential associationPediatric Nephrology, 2011